Oxy295

Oxy295 is a semi-synthetic oxysterol small molecule developed by MAX BioPharma. It functions as an agonist of the Smoothened (Smo) receptor, a key component of the Hedgehog (Hh) signaling pathway. By activating this pathway, Oxy295 promotes the differentiation of osteoprogenitor cells into osteoblasts, thereby stimulating bone formation and regeneration. The compound is currently in preclinical development for orthopedic indications, including spinal fusion, bone fracture healing, and the regeneration of bone defects. Notably, the FDA has classified Oxy295 as a medical device for these specific applications, reflecting its likely administration via a carrier or scaffold at the site of injury.